Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Ignacio Melero(University of Oxford), Thomas F. Gajewski(University of Chicago Medical Center), Marco Sanduzzi‐Zamparelli(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Kira‐Lee Koster(University of St.Gallen), Andreas M. Schmitt(University of Basel), Felix K.‐H. Chun(Universität Hamburg), Egle Ramelyte(University of Zurich), Alberto Hernando‐Calvo(Hebron University), Henning Reis(Goethe University Frankfurt), J.J. Soto Castillo(Institut Català d'Oncologia), Jorge Esteban-Villarrubia(Research Institute Hospital 12 de Octubre), Fabricio Racca(Instituto Oncológico Dr. Rosell), David König(University Hospital of Basel), Markus Joerger(Kantonsspital St. Gallen), Peter J. Wild(Goethe University Frankfurt), Guzmán Alonso(Vall d'Hebron Hospital Universitari), Dagmar Hess(Kantonsspital St. Gallen), A. Vilalta(Clinica Universidad de Navarra), Heinz Läubli(University of Basel), Martin Schüler(German Cancer Research Center), Cyrus Sayehli(Universitätsklinikum Würzburg), Heike Richly(Universitätsklinik Marien Hospital Herne), Matthias Macháček, Florestan Koll(Technical University of Munich), Hubert Hackl(Innsbruck Medical University), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Javier Torres-Jiménez(Hospital Universitario 12 De Octubre), Juan Martín-Liberal(Institut d'Investigació Biomédica de Bellvitge), Elena Garralda(Memorial Sloan Kettering Cancer Center), Ana Landa-Magdalena(Clinica Universidad de Navarra), A. Oberoi(Hebron University), Peter R. Galle(Johannes Gutenberg University Mainz), Falk Gogolla(Innsbruck Medical University), Irene Moreno, Tanja Gromke(National Center for Tumor Diseases), Corinne Eggenschwiler(University Hospital Zurich), María Reig(Hospital Clínic de Barcelona), Christine Koch(University Health Network), Marta Fortuny(Hospital Clínic de Barcelona), Zlatko Trajanoski(Innsbruck Medical University), Reinhard Dummer(University Hospital of Zurich), Omar Saavedra(Hospital Quirónsalud Barcelona), Paula Sàbat(Institut Català d'Oncologia), Guillermo de Velasco(Dana-Farber Cancer Institute), Jörg Trojan(Goethe University Frankfurt), Maria-Elisabeth Goebeler(Universitätsklinikum Würzburg), Maria de Miguel Luken, Peter Lloyd(Alexza Pharmaceuticals (United States)), Friedrich Foerster(Johannes Gutenberg University Mainz)
Cited by 107
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k